Document:

EX-10.7

 Exhibit 10.7 

 
  
 THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 
 This Third Amendment to Exclusive License Agreement (“Thir d Amendment”), dated as of June 12, 2006, is made by and among The Regents of the University of California, a
California corporation (“The Regents”), Medivation, Inc., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc, a Delaware corporation and subsidiary of Medivation (“MPT”) (Medivation and MPT
together “Licensee”). 
 BACKGROUND 

A. The Regents, Medivation and MPT are parties to an Exclusive License Agreement, dated as of August 12, 2005 (the
“Exclusive License Agreement”), as amended on November 4, 2005 and May 8, 2006, 
 B The
Regents and MPT are parties to a Nonexclusive Bailment and License Agreement dated October 27, 2005 (the “Nonexclusive Bailment”) that grants to MPT limited rights in a certain Field of Use to patent rights generally characterized as
“Methods and Materials for Assessing Prostate Cancer Therapies’’ (UCLA Case No. 2003-279), which was made in the cour se of research at the Univer sity of California, L os Angeles by Charles L Sawyers, Charlie D, Chen and Derek S
Welsbie, employees of The Regents, MPT now wishes to obtain broader nonexclusive rights to these patent rights in the United States and exclusive rights to these patent rights in certain countries and regions outside the United States in a different
field of use. The Regents is willing to grant such rights, This Third Amendment is not intended to change the scope of rights gr anted under the Nonexclusive Bailment , 
 C Medivation as the par ent corpor ation of MPT will benefit dir ectly from the agr eements made herein 
 D The parties mutually intend to enter into this Third Amendment to amend the terms of the 
 Exclusive License Agreement, as specified below 

THEREFORE, the parties hereby agree as follows: 

	 1
	  
	 Paragr aph 1,1 (“Regents’ Patent Rights”) is deleted and r eplaced with the following, which is

 amended to include “UC Case No. 2003-279-2” in the parenthetical at the end
of the paragraph: 

	 1
	  
	 1 “Regents’ Patent Rights” means The Regents’ inter est in the claims of the United States
patents and patent applications, corresponding foreign patents and patent applications (requested under Paragraph 7 3 herein), and any reissues, extensions, substitutions, continuations, divisions, and continuation-in-part applications (but only
those claims in the continuation-in-part applications that ar e entirely supported in the specification and entitled to the priority date of the par ent application) based on the patent applications listed in Appendix A (UC Case Nos 2003-279-2,
2004- 129, 2005-438, 2006-260 and 2006-537) 

 

 
  

	 •
	  
	 Paragraph 2 1 is deleted and replaced with the following, which is amended to giant nonexclusive lights in the
United States and exclusive rights outside the United States to the patent rights covered by UC Case No 2003-279-2: 

 2.1 Subject to the limitations set foith in this Agreement, including the licenses granted to the United States Government and those reserved by HHMI set forth in the recitals and in
Paragraph 2,2 and the rights reserved by The Regents in Paragraph 2 ,3, The Regents hereby grants to MPT an exclusive license (the “License”) under Regents’ Patent Rights, in jurisdictions where Regents’ Patent Rights exist, to
make, have made, use, sell, offer for sale and import Licensed Products and to practice Licensed Methods in the field of Use to the extent permitted by law; provided, however, that as to UC Case No, 2003-279-2 only, the License shall be exclusive
only in Australia, Canada, the European Union, Japan and New Zealand, and shall be non-exclusive in the United States 

	 •
	  
	 Appendix A (Regents’ Patent Rights) is deleted and r eplaced with the Appendix A attached

 to this Third Amendment, which is amended to include the patent applications to be filed

 under UC Case No 2003-279-2 in Australia, Canada, the European Union, Japan, New 

Zealand and the United States 

	 •
	  
	 In consideration for the addition of the patent rights of UC Case No 2003-279-2 to the

 Exclusive License Agreement, Licensee will pay to The Regents a fee of two thousand five
hundred dollars ($2,500) within thirty (30) days of the Effective Date of this Third 
 Amendment In
addition, Licensee will pay a one-time milestone fee of twenty-five 
 thousand dollars ($25,000) upon issuance
of the first patent under UC Case No 2003-279-2 in Australia, Canada, the European Union, Japan or New Zealand that would cover a Licensed Product. 

	 •
	  
	 Article 7 (Patent Filing, Prosecution and Maintenance) is amended to include a new Paragraph 7,7:

	 7
	  
	 7 Notwithstanding the foregoing provisions in this Article 7, Licensee is not obligated to reimburse costs
incur red prior to and during the term of this Agreement in the pr epar ation, filing, pr osecution and maintenance of patent applications and patents pertaining to the United States patent rights of UC Case No 2003-279-2 within Regents’ Patent
Rights Further, The Regents has no obligation to prosecute or maintain the United States patent rights of UC Case No 2003-279-2 within Regents’ Patent Rights . If The Regents elects to abandon the United States patent rights of UC Case No
2003-279-2 within Regents’ Patent Rights, then the consideration due to The Regents under this Agreement shall remain the same. 

 

 
  

	 6
	  
	 Except for the amendments specifically referenced above, all other terms of the Exclusive License Agreement
shall remain unchanged and in full force and effect 

 AU/V 

The Regents, Medivation and MPT have executed this Amendment in duplicate originals by their authorized officers on the
dates written below: 
 /s/ Patrick Machado 

/s/ Patrick Machado 
 /s/ Claire T. Wake, PH.D. 

 

 
  
 APPENDIX A
(Third Amendment) 
 REGENTS1 PATENT RIGHTS 

UC Case No. 2003-279-2 
 Australian Patent Application No., [TBD] to be filed Canadian Patent Application No [TBD] to be filed European Patent Application No [TBD] to be filed Japanese Patent Application No. [TBD]
to be filed New Zealand Patent Application No,, [TBD] to be filed United States Patent Application No, [TBD] to be filed 
 All of the above based on PCT Patent Application No. US04/42221 “Method and Materials for Assessing Prostate Cancer Therapies,” filed December 16, 2004 and assigned to The
Regents, The inventors are Charles L, Sawyers, an employee of the Howard Hughes Medical Institute (“HHMI”) and a member of the faculty of The Regents, and Charlie D Chen and Derek S Welsbie, employees of The Regents 

UC Case No. 2004-129 
 PCT Patent Application No. US05/05529 “Methods and Materials for Assessing Prostate Cancer Therapies and Compounds,” filed February 23, 2005, based on US Provisional Patent
Application No. 60/547,101 filed February 24, 2004 and assigned to The Regents,, The inventors are Michael E Jung, Samedy Ouk, Char lie D, Chen and Der ek Welsbie, employees of The Regents, and Char les L, Sawyers, an employee of the
Howard Hughes Medical Institute (“HHMI”) and a member of the faculty of The Regents,, 
 UC Case
No. 2005-438 
 US Provisional Patent Application No. 60/680,8.35 “Novel Androgen Receptor
Inhibitors with Minimal Agonistic Activities” filed May 13, 2005 and assigned to The Regents, The inventors are Michael E. Jung, Samedy Ouk, Charlie D Chen and Derek Welsbie, employees of The Regents, and Charles L Sawyers, an employee of
the Howard Hughes Medical Institute (“HHMI”) and a member of the faculty of The Regents This application, together with the patent application pertaining to UC Case No 2004-129, cover the compounds identified as RD1 through RD138,
inclusive, on Exhibit A attached to the First Amendment. 
 PCT Patent Application No. PCT/US06/11417 (also
includes UC Case Nos. 2006-260 & 2006- 537) titled “Diarylthiohydantoin Compounds” was filed March 29, 2006 and assigned to The Regents The inventors are Michael E Jung, Samedy Ouk, Charlie D. Chen, Derek Welsbie and Dongwon
Yoo, employees of The Regents, and Charles L Sawyers, an employee of Howard 
 Hughes Medical Institute
(“HHMI”) and a member of’ the faculty of the University of California, Los Angeles, and John Wongvipat and Chris Tran, employees of HHMI. 

 

 
  
 UC Case
No. 2006-260 
 US Provisional Patent Application No. 60/750,351 filed December 15, 2005 and US
Provisional Patent Application No. 60/756,552 filed January 6, 2006, both titled “Selected 

Diarylthiohydantoin Compounds” filed January 6, 2006 (both were subsequently rolled into PCT Patent Application
No. PCT/US06/11417), and both assigned to The Regents The inventors are Michael E Jung, Samedy Ouk and Charlie D Chen, employees of The Regents, and Charles L Sawyers, an employee of the Howard Hughes Medical Institute (“HHMI”) and a
member of the faculty of The Regents, and John Wongvipat and Chris Tran, employees of HHMI 
 UC Case
No. 2006-537 
 US Provisional Patent Application No. 60/786,837 “Diarylthiohydantoin
Compounds” filed March 29, 2006 and assigned to The Regents, (This invention was also filed as part of PCT Patent Application No PCT/US06/11417, listed under UC Case No 2005-438 above), The inventors are Michael E„ Jung and Dongwon
Yoo, employees of The Regents, and Charles L Sawyers, an employee of Howard Hughes Medical Institute (“HHMI”) and a member of the faculty of the University of California, Los Angeles, and Chris Tr an, an employee of HHMIEX-10.8

 Exhibit 10.8 

 
  
 Four th
Amendment To Exclusive License Agreement Between 
 The Regents of the University of California 

and 
 Medivation, Inc and Medivation Prostate Therapeutics, Inc 
 For 
 UC Agreement Control No. 2006-04-0085

 

 
  
 FOURTH
AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 
 This Fourth Amendment to
Exclusive License Agreement (“Fourth Amendment”), dated as of July 17, 2007, is made by and among The Regents of the University of California, a California corporation (“The Regents”), Medivation, Inc , a Delaware
corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc,, a Delaware corporation and subsidiary of Medivation (“MPT”) (Medivation and MPT together “Licensee”) 

BACKGROUND 
 A The Regents, Medivation and MPT are parties to an Exclusive License Agreement, dated as 
 of August 12, 2005 (the “Exclusive License Agreement”), as amended on November 4, 2005, May 8, 2006 and June 12, 2007 , 

B Medivation has supported research in Dr. Michael E Tung’s laboratory at UCLA under a 

Sponsor ed Resear ch Agreement with an Effective Date of August 12, 2005 (the “Sponsored Research
Agreement”) 
 C An invention has been developed at UCLA in the performance of the Sponsored Research

 Agreement, which is disclosed in UC Case No. 2007-139 entitled “Additional Thiohydantoin Androgen
Receptor Antagonists for Prostate Cancer Treatment,” by Michael E, Jung and Dongwon Yoo, employees of The Regents, Charles L. Sawyers, an employee of Howard Hughes Medical Institute (“HHMI”) and a member of the faculty of the
University of California, Los Angeles at the time the invention was made, and Chris Tran, an employee of HHMI at the time the invention was made, 
 D, The Sponsored Research Agreement grants Medivation the first right to negotiate for a 
 license to inventions made by The Regents in the performance of the Sponsored Research Agreement, and Medivation has exercised its right and wishes to obtain an exclusive license to the
invention noted in the preceding clause , 
 E Medivation as the parent corporation of MPT will benefit directly
from the agreements made 
 herein 
 F The parties mutually intend to enter into this Fourth Amendment to amend the terms of the 
 Exclusive License Agreement, as specified below 

THEREFORE, the parties hereby agree as follows: 

	 1
	  
	 Paragraph 11 (“Regents’ Patent Rights”) is deleted and replaced with the following, which

 is amended to include “UC Case No 2007-139” in the parenthetical at the end of the
paragraph: 

 

 
  
 11
“Regents’ Patent Rights” means The Regents’ interest in the claims of the United States patents and patent applications, corresponding foreign patents and patent applications (requested under Paragraph 7.3 herein), and any
reissues, extensions, substitutions, continuations, divisions, and continuation-in-part applications (but only those claims in the continuation-in-part applications that are entirely supported in the specification and entitled to the priority date
of the parent application) based on the patent applications listed in Appendix A (UC Case Nos 2003-279-2, 2004- 129, 2005-438, 2006-260, 2006-537 and 2007-139) 

	 •
	  
	 Appendix A (Regents’ Patent Rights) is deleted and replaced with the Appendix A attached to this Fourth
Amendment, which is amended to include the patent applications to be filed under UC Case No 2007-139 

	 •
	  
	 In consideration for the addition of the patent rights of UC Case No 2007-139 to the

 Exclusive License Agreement, Licensee will pay to The Regents a fee of two thousand five
hundred dollars ($2,500) within thirty (30) days of the Effective Date of this Fourth Amendment In addition, Licensee will pay a one-time milestone fee of twenty-five thousand dollars ($25,000) upon issuance of the first patent under UC Case No
2007-139 that would cover a Licensed Product,, 
 The Regents, Medivation and MPT have executed this Amendment in
duplicate originals by their 
 authorized officers on the dates written below: 

MEDIVATION, INC. 
 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 
 By (

 Name 
 C Patrick Machado 
 Name 

Claire T Wake, Ph D 
 Title Senior Vice President and CFO Title 

Assistant Director , Licensing Date 
 8 Aug 07 
 Date July 19, 2007 MEDIVATION PROSTATE
THERAPEUTICS, INC By /s/ C. Patrick Machado 
 Name C Patrick Machado 

Title Senior Vice President and CFO Date /s/ C. Patrick Machado 

/s/ Claire T. Wake, Ph.D. 

 

 
  
 APPENDIX A
(Fourth Amendment) 
 REGENTS PATENT RIGHTS 

UC Case No. 2003-279-2 
 United States Patent Application No 10/583,280 filed December 16, 2004 Australian Patent Application No . 2004-305075 filed December 16, 2004 Canadian Patent Application No
2550447 filed December 16, 2004 European Patent Application No 04814409 1 filed December 16, 2004 Hong Kong Patent Application No 7103115 7 filed December 16, 2004 Japanese Patent Application No . 2006-545417 filed December 16,
2004 New Zealand Patent Application No , 548209 filed December 16, 2004 
 All of the above based on PCT
Patent Application No,. US04/42221 “Method and Mater ials for Assessing Prostate Cancer Therapies,” filed December 16, 2004, based on US Provisional Patent Application No. 60/5.31,091 filed on December 19, 2003 and assigned
to The Regents The inventors are Charles L, Sawyers, an employee of the Howard Hughes Medical Institute (“HHMI”) and a member of the faculty of The Regents, and Charlie D , Chen and Der ek S., Welsbie, employees of The Regents 

UC Case No. 2004-129 
 United States Patent Application No 10/590,445 filed February 23, 2005 Australian Patent Application No, 2005-232526 filed February 23, 2005 New Zealand Patent Application No
550102 filed February 23, 2005 
 All of the above based on PCT Patent Application No. US05/05529
“Methods and Materials for Assessing Prostate Cancer Therapies and Compoundsfiled February 23, 2005, based on US Provisional Patent Application No. 60/547,101 filed February 24, 2004 and assigned to The Regents, The inventors are
Michael E Jung, Samedy Ouk, Charlie D. Chen and Derek Welsbie, employees of The Regents, and Charles L. Sawyers, an employee of the Howard Hughes Medical Institute (“HHMI”) and a member of the faculty of The Regents 

United States Patent Application No 11/433,829 filed March 29, 2006 

The above based on PCT Patent Application No. PCT/US06/11417 “Novel Androgen Receptor Inhibitors with Minimal
Agonistic Activities,” filed on March 29, 2006, based on US Provisional 

 

 
  
 Patent
Application No. 60/680,835 filed May 13, 2005 and assigned to The Regents The inventors are Michael E. Jung, Samedy Ouk, Charlie D Chen and Derek Welshie, employees of The Regents, and Charles L Sawyers, an employee of the Howard Hughes
Medical Institute (“HHMI”) and a member of the faculty of The Regents. This application, together with the patent application pertaining to UC Case No. 2004-129, cover the compounds identified as RD1 through RD138, inclusive, on
Exhibit A attached to the First Amendment 
 PCT Patent Application No. PCT/US06/11417 (also includes UC Case
Nos. 2006-260 & 2006- 537) titled “Diarylthiohydantoin Compounds” was filed March 29, 2006 and assigned to The Regents The inventors are Michael E Jung, Samedy Ouk, Charlie D Chen, Derek Welsbie and Dongwon Yoo, employees of
The Regents, and Charles L Sawyers, an employee of Howard Hughes Medical Institute (“HHMI”) and a member of the faculty of the University of California, Los Angeles, and John Wongvipat and Chris Tran, employees of HHMI, 

UC Case No. 2006-260 

US Provisional Patent Application No, 60/750,351 filed December 15, 2005 and US Provisional

 Patent Application No. 60/756,552 filed January 6, 2006, both titled “Selected 

Diarylthiohydantoin Compounds “ filed January 6, 2006 (both were subsequently rolled into PCT Patent Application
No PCT/US06/11417), and both assigned to The Regents, The inventors are Michael E Jung, Samedy Ouk and Charlie D Chen, employees of The Regents, and Charles L Sawyers, an employee of the Howard Hughes Medical Institute (“HHMI”) and a
member of the faculty of The Regents, and John Wongvipat and Chris Tran, employees of HHMI. 
 UC
Case No. 2006-537 
 United States Patent Application No 11/730,168 filed March 29, 2007 

The above based on PCT Patent Application No. PCT/US07/07854 “Diarylthiohydantoin Compounds” filed on
March 29, 2007, based on US Provisional Patent Application No. 60/786,837 filed March 29, 2006 and assigned to The Regents (This invention was also filed as part of PCT Patent Application No, PCT/US06/11417, listed under UC Case No
2005-438 above), The inventors are Michael E, Jung and Dongwon Yoo, employees of The Regents, and Charles L Sawyers, an employee of Howard Hughes Medical Institute (“HHMI”) and a member of the faculty of the University of California, Los
Angeles, and Chris Tr an, an employee of HHMI , 
 UC Case No. 2007-139 

US Provisional Patent No. [TBD] to be filed “Additional Thiohydantoin Androgen Receptor Antagonists for Prostate
Cancer Treatment, “ The inventors are Michael E„ Jung and Dongwon Yoo, employees of The Regents, and Char les L. Sawyer s, an employee of HHMI and a member of the faculty of the University of California, Los Angeles, and Chris Tr an,
employee of HHMI , 
 RD4 
 RD162

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}]]